Year: 2025
Type: article
Study design: Case Report
Abstract: The present study aimed to analyze the efficacy of personalized combination therapy for patients with H3K27M mutant diffuse midline glioma (DMG) so as to explore new treatment options for further clinical research. The clinical data and prognosis of a patient with H3K27M mutant DMG are summarized and discussed in the context of the relevant literature. The patient was a 20-year-old female diagnosed with DMG treated with a combination of surgery, radiotherapy, chemotherapy, electric field therapy, immunotherapy and targeted therapy. An overall survival time of 28 months was achieved. In summary, personalized treatment strategies are expected to provide longer-lasting survival benefits for patients with DMG.
Source: Oncology Letters
Authors: Mengqi Sun, Jizhou Zheng, Long Gong, Zihuang Li, Lijun Wang
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408528350